Nanoscope Therapeutics to Present at AAO 2025 Annual Meeting
DALLAS /Nanoscope Therapeutics Inc., a forward-thinking biotechnology company, is focused on creating and commercializing groundbreaking therapies aimed at addressing vision loss due to retinal degeneration. As part of this commitment, the company is set to make multiple important presentations at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting, taking place in Orlando.
Details of the Presentations
These presentations will occur over several days, starting on October 16, 2025, as part of the Eyecelerator event at the AAO Annual Meeting. Nanoscope's innovative Multi-Characteristic Opsin (MCO) platform will be highlighted, specifically targeting patients suffering from severe vision loss due to retinitis pigmentosa (RP) and Stargardt disease (SD). These serious conditions currently lack approved treatment options.
Session Highlights
The first of these significant presentations is titled "Nanoscope Therapeutics Company Showcase," where the latest advancements in the field will be discussed. This session will take place on October 16, 2025, from 1:40 to 1:45 p.m. EDT at Location W230, presented by Samuel Barone, MD, the Chief Medical Officer of the company.
Another crucial session will cover the "152-Week REMAIN Data from Extended Analysis of MCO-010 RESTORE Study of Optogenetic Therapy for Retinitis Pigmentosa," scheduled for October 18, 2025, at 8:11 a.m. EDT in W415 Valencia. Allen C. Ho, MD, an esteemed surgeon and Director of Retina Research at Wills Eye Hospital, will be leading this important discussion.
Significant Breakthroughs in Stargardt Disease
A presentation focusing on "Visual Improvement Across Multiple Assessments with MCO-010 Optogenetic Therapy for Stargardt Disease" will occur later that same day, from 1:45 to 2:15 p.m. EDT at Hall WB4, Station 1. This session will be presented by renowned retina specialist Kenneth C. Fan, MD.
Final Presentation Details
Wrapping up the event, on October 20, 2025, from 8:30 to 8:45 a.m. EDT in W311E, Nanoscope will present on "Optogenetic Therapy in Adults with Retinitis Pigmentosa and Stargardt Disease." This session features a collaborative presentation by notable experts in the field including Samarendra Mohanty, PhD, and Stephen Tsang, MD, PhD.
CEO Insights
"We are excited to share the latest data from our MCO-010 studies at the AAO and Eyecelerator 2025," stated Sulagna Bhattacharya, the Chief Executive Officer of Nanoscope Therapeutics. "These presentations reflect the robust nature of our clinical efforts and regulatory progress. With our rolling Biologics License Application for RP currently in progress, coupled with five recent orphan designations from the European Medicines Agency, we are working diligently to advance MCO-010 to patients affected by devastating retinal diseases."
About the MCO Platform
The MCO platform is designed as a one-time, in-office therapy aimed at restoring vision in patients with photoreceptor degeneration. This revolutionary treatment approach is applicable to various retinal conditions, including retinitis pigmentosa and Stargardt disease, circumventing the need for complex genetic testing or invasive procedures. The platform relies on activating the remaining healthy retinal cells to restore visual function.
About Nanoscope Therapeutics
Nanoscope Therapeutics is at the forefront of developing vision-restoring optogenetic therapies for patients with retinal degenerative conditions. Their ongoing research and clinical trials highlight the potential of their flagship treatment MCO-010, which is currently under regulatory review and showing promise in clinical studies.
Frequently Asked Questions
What is Nanoscope Therapeutics working on?
Nanoscope Therapeutics is developing innovative therapies for retinal degeneration, particularly targeting conditions like retinitis pigmentosa and Stargardt disease.
When will the AAO 2025 Annual Meeting take place?
The American Academy of Ophthalmology Annual Meeting is scheduled for October 18-20, 2025.
What is the MCO platform?
The MCO platform is a one-time treatment designed to restore vision in individuals with photoreceptor degeneration.
Who are the presenters at the AAO event?
Presenters include experts such as Samuel Barone, MD, and Allen C. Ho, MD, among others.
What does MCO-010 aim to achieve?
MCO-010 aims to provide a new standard of care for patients with vision loss due to retinal diseases, administered as an office-based injection.
